Cipla Urged by Voluntary Group to Reduce AIDS Drug Price

by VR Sreeraman on August 24, 2007 at 8:02 PM
Cipla Urged by Voluntary Group to Reduce AIDS Drug Price

An international voluntary group active in treating HIV/AIDS patients Friday appealed to pharma major Cipla to reduce the price of AIDS drugs.

The US-based AIDS Healthcare Foundation said that out of the 2.5 million Indians suffering from HIV/AIDS, 85,000 are receiving antiretroviral treatment.


Quoting Médecins Sans Frontières, an international medical and humanitarian aid organisation, the foundation claimed that Cipla provides African countries with AIDS drugs much cheaper than it provides to Indians.

"While Cipla offers African nations the same drug for Rs.21,200 (per person per year), it is available in India for Rs.54,000," said Chinkholal Thansing, Asia Pacific bureau chief of the foundation.

The organisation said the per capita gross national income (GNI) in India was roughly $730, while Cipla's published price in India for the AIDS drug Viraday was around $1,344, nearly twice the average Indian's annual income.

In this connection, the AIDS Healthcare Foundation (AHF) had published an advertisement in a number of newspapers. Reacting to this Cipla had already sent a legal notice to AHF asking it to publish a public apology or else face a defamation case worth $25 million.

"We are a voluntary group and have no rivalry with Cipla. Though we appreciate Cipla for developing antiretroviral drugs but we will not apologise to it," Thansing said.

Source: IANS
Font : A-A+



Recommended Readings

Latest Drug News

Can a Needle-Free Patch Transform Zika Protection?
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Prolonging Market Exclusivity of Brand-name Insulin
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
FDA Boosts Orphan Drug Designations for Myelofibrosis Treatments
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
Anti-Rheumatic Drugs May Help Prevent Thyroid Disease
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Apotransferrin's Potential in Early Stroke Therapy Revealed
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Cipla Urged by Voluntary Group to Reduce AIDS Drug Price Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests